

Sheet 1 of 3

| | | | |
|--|--|---------------------|------------------|
| SUBSTITUTE FORM PTO-1449 (MODIFIED) | U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE | Attorney Docket No. | 50701/003002 |
| | | Serial No. | 09/699,003 |
| | | Applicant | M. Rigdon Lentz |
| | | Filing Date | October 26, 2000 |
| | | Group | 3761 |
| | | IDS Filed | July 6, 2010 |

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Use several sheets if necessary)

(37 C.F.R. § 1.98(b))

U.S. PATENT DOCUMENTS

| Examiner's Initials | Document Number | Publication Date | Patentee or Applicant |
|---------------------|-----------------|------------------|-----------------------|
| | 4,787,974 | Nov. 29, 1988 | Ambrus, et al. |
| | 5,340,736 | Aug. 23, 1994 | Goldberg, et al. |
| | 5,925,633 | Jul. 20, 1999 | Singh, et al. |
| | 5,965,394 | Oct. 20, 1994 | Bandman, et al. |
| | 6,720,155 | Apr. 13, 2004 | Lopez, et al. |
| | 12/685,307 | N/A | Lentz |
| | 2008/0057060 | Mar. 6, 2008 | Lentz |
| | 2008/0145333 | Jun. 19, 2008 | Lentz |

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

| Examiner's Initials | Document Number | Publication Date | Country or Patent Office | Translation (Yes/No) |
|---------------------|-----------------|------------------|--------------------------|----------------------|
| | CA 2107340 | Dec. 20, 1992 | Canada | |

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)

| | |
|--|---|
| | Ammirati et al., "Detection of TNF inhibitors (soluble receptors) in the sera and tumor cyst fluid of patients with malignant astrocytomas of the brain" Front Biosci Oct 1;6:B17-24 (2001). |
| | Burger et al., "Association between serum levels of soluble tumor necrosis factor receptors/CA 125 and disease progression in patients with epithelial ovarian malignancy: a gynecologic oncology group study" Cancer 101(1):106-15 (2004). |
| | Chen et al., "Experimental vaccine strategies for cancer immunotherapy" J Biomed Sci 5(4):231-52 (1998). |
| | Csehi et al., "Tumor necrosis factor (TNF) interferes with insulin signaling through the p55 TNF receptor death domain." Biochem Biophys Res Commun. 2005 Apr 1;329(1):397-405. |
| | Eisen, "General Immunology", J.B. Lippincott Company, 78 (1980). |

EXAMINER /Leslie Deak/

DATE CONSIDERED 07/08/2010

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /LD/

Sheet 2 of 3

| | | | |
|--|--|---|---|
| SUBSTITUTE FORM PTO-1449 (MODIFIED) INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. § 1.98(b)) | U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE | Attorney Docket No. Serial No. Applicant Filing Date Group IDS Filed | 50701/003002 09/699,003 M. Rigdon Lentz October 26, 2000 3761 July 6, 2010 |
|--|--|---|---|

| OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION) | |
|---|--|
| | Feng, "Regulatory roles and molecular signaling of TNF family members in osteoclasts." Gene. 2005 Apr 25;350(1):1-13. |
| | Gonzalez et al., "A novel cancer vaccine composed of human-recombinant epidermal growth factor linked to a carrier protein: report of a pilot clinical trial" Ann Oncol 9(4):431-5 (1998). |
| | Holtmann et al. "The emerging distinct role of TNF-receptor 2 (p80) signaling in chronic inflammatory disorders." Arch Immunol Ther Exp (Warsz). 2002;50(4):279-88. |
| | Kirchels et al., "Cytokine gene-modified tumor cells for prophylactic and therapeutic vaccination: IL-2, IFN-gamma, or combination IL-2 + IFN-gamma" Cytokines Cell Moll Ther 4(2):95-103 (1998). |
| | "Laboratory Filtration Concepts," Pall Life Sciences, http://www.pall.com/catalogs/filterbook/concepts.asp , retrieved April 12, 2002. |
| | Liu et al. "Molecular mechanism of TNF signaling and beyond." Cell Res. 2005 Jan;15(1):24-7. |
| | Mack et al., "Five-year results of a phase II study with low-dose bacille Calmette-Guerin therapy in high-risk superficial bladder cancer" Urology 45(6):958-61 (1995). |
| | Maier et al., "Physiological levels of pro- and anti-inflammatory mediators in cerebrospinal fluid and plasma: a normative study" J Neurotrauma 22(7):822-35 (2005) |
| | Moller et al., "Vaccination with IL-7 gene-modified autologous melanoma cells can enhance the anti-melanoma lytic activity in peripheral blood of patients with a good clinical performance status: a clinical phase I study" Br J Cancer 77(11):1907-16 (1998). |
| | Mordoh et al. "Allogeneic cells vaccine increases disease-free survival in stage III melanoma patients. A non randomized phase II study" Medicina (B Aires) 57(4):421-7 (1997). |
| | Moviglia "Development of tumor B-cell lymphocyte hybridoma (TBH) autovaccination. Results of phase I-II clinical trial" Transfus Sci 17(4):643-9 (1996). |
| | Muc-Wierzon et al. "Circadian fluctuations of melatonin, tumor necrosis factor-alpha and its soluble receptors in the circulation of patients with advanced gastrointestinal cancer" J Exp Clin Cancer Res. 2003 Jun;22(2):171-8. |
| | Rzymnski et al. "Serum tumor necrosis factor alpha receptors p55/p75 ratio and ovarian cancer detection." Int J Gynaecol Obstet. 2005 Mar;88(3):292-8. |
| | Sasaki et al., "Identification of a soluble GM-CSF binding protein in the supernatant of a human choriocarcinoma cell line," Biochem. Biophys. Res. Commun. 183(1):252-257 (1992). (Abstract Only) |
| | Serwin et al. "[Soluble tumor-necrosis-factor-alpha receptor type-1 as a marker of activity of psoriasis vulgaris and effects of its treatment]" Przegl Lek. 2005;62(2):95-7. |

| | |
|---|----------------------------|
| EXAMINER /Leslie Deak/ | DATE CONSIDERED 07/08/2010 |
| EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant. | |

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /LD/

Sheet 3 of 3

| | | | |
|---|---|---------------------|------------------|
| SUBSTITUTE FORM PTO-1449 (MODIFIED) | U. S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE | Attorney Docket No. | 50701/003002 |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) | | Serial No. | 09/699,003 |
| | | Applicant | M. Rigdon Lentz |
| | | Filing Date | October 26, 2000 |
| | | Group | 3761 |
| (37 C.F.R. § 1.98(b)) | | IDS Filed | July 6, 2010 |

| | |
|--|--|
| | Serwin et al. "Soluble tumor necrosis factor alpha receptor type 1 in psoriasis patients treated with narrowband ultraviolet B" Photodermatol Photoimmunol Photomed. 2005 Aug;21(4):210-1. |
| | Shai et al. "A prospective study of soluble tumor necrosis factor-alpha receptor II (sTNF-RII) and risk of coronary heart disease among women with type 2 diabetes." Diabetes Care. 2005 Jun;28(6):1376-82. |
| | Sinclair, "Filtration Fundamentals: Is Knowledge Of Filter Technology Something You Let Fall Through The Cracks?" The Scientist 12[19]:18 (1998), http://www.the-scientist.com/yr1998/sept/profile1_980928.html , retrieved on April 12, 2002. |
| | Sivanandham et al., "Colon cancer cell vaccine prepared with replication-deficient vaccinia viruses encoding B7.1 and interleukin-2 induce antitumor response in syngeneic mice" Cancer Immunol Immunother 46(5):261-7 (1998). |
| | Sukhikh et al. "Disorders in cytokine gene expression in endometrial hyperplasia and effect of hormone therapy." Bull Exp Biol Med. 2005 Feb;139(2):235-7. |
| | Talwar "Vaccines for control of fertility and hormone-dependent cancers" Immunol Cell Biol 75(2):184-9 (1997). |
| | Thiess et al. "Tumor necrosis factor (TNF) alpha increases collagen accumulation and proliferation in intestinal myofibroblasts via TNF receptor 2." J Biol Chem. 2005 Oct 28;280(43):36099-109. Epub 2005 Sep 1. |
| | Wajant et al. "Tumor necrosis factor signaling." Cell Death Differ. 2003 Jan;10(1):45-65. |
| | Wozel "Etanercept. An effective TNF alpha-antagonist in the treatment of psoriatic arthritis and chronic plaque psoriasis" Hautarzt. 2005 Sep;56(9):819-30. |

| | |
|---|----------------------------|
| EXAMINER /Leslie Deak/ | DATE CONSIDERED 07/08/2010 |
| EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant. | |

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /LD/